ClinicalTrials.gg
RecruitingNCT06267040Updated Apr 16, 2024

Linguistic and Clinical Validation of the Arabic Version of Acute Cystitis Symptom Score (ACCS)

An observational study in Cystitis Acute, sponsored by Al-Kindy College of Medicine. Recruiting at 2 sites in Iraq. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-16.

Sponsored by Al-Kindy College of Medicine · Observational

From the registry’s dates

  • Primary completion was expected by Apr 2024, 2 years 6 months ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 2 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
Female
01

Study summary

The goal of this prospective observational study is to provide an Arabic translation of the Acute Cystitis Symptom Score (ACSS) and to test the linguistic validity and clinical reliability of the translated Arabic version of ACCS (Arabic-ACCS) in Arabic-speaking women older than 18 years of age diagnosed with uncomplicated cystitis.

The main questions it aims to answer are:

  • Do the questions of the Arabic-ACSS have sufficient clarity?
  • Can the Arabic-ACCS serve its purpose in identifying the presence of uncomplicated cystitis in Arabic-speaking women? The participant will be asked to fill out the Arabic-ACCS questionnaire at the time of diagnosis. The participants will be asked to fill out the second part of the Arabic-ACCS questionnaire 5-10 days later after receiving the appropriate treatment according to the local health policy as prescribed by the treating physician.

Researchers will compare the results from the patients who filled out the first part of the questionnaire with the results of a comparable group of women who were presented with complaints unrelated to the lower urinary tract.

02

Conditions studied

  • Cystitis Acute

Browse trials for

Keywords

  • uncomplicated cystitis
  • linguistic validation
  • Acute Cystitis symptom score
  • ACSS
03

In context

Cystitis

69 studies on the registry are indexed under Cystitis; 17 are open to participants now.

This study's planned enrollment of 200 is close to the median of 216 across 15 observational studies indexed under Cystitis.

Browse Cystitis studies →

Lead sponsor

Al-Kindy College of Medicine is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Sampling method
Non-probability sample

Study population

Women presented to the urology or gynecology and obstetrics outpatient clinics at Alkindy Teaching Hospital and Al-Elwiya Maternity Teaching Hospital having the diagnosis of uncomplicated cystitis will serve as the case group.

In addition, a control group of women attending the same clinics who are complaining of conditions unlikely to affect the symptoms of the lower urinary tract will be recruited as a control group

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women.
  • presented to the urology or gynecology and obstetrics outpatient clinics.
  • having the diagnosis of uncomplicated cystitis.

Exclusion criteria

Exclusion Criteria:

  • pregnancy.
  • urethral catheterization.
  • anatomical abnormality of the urinary tract.
  • Neurologic abnormality that affects bladder function.
  • urinary tract stones.
  • recent antibiotic usage (within 1 month).
  • .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • women diagnosed with uncomplicated cystitis

    women older than 18 years diagnosed with uncomplicated cystitis and treated accordingly

  • control group

    women older than 18 years presented for reasons unlikely to affect the lower urinary tract

06

What researchers measure

Primary outcomes

  1. Linguistic validity

    Each question in the translated Arabic version of the Acute Cystitis Symptom Score questionnaire should be clear, and the answer to the question should provide the desired piece of information. The acute cystitis symptom score questionnaire consists of four domains at the first visit. These domains ask about typical symptoms (6 questions), differential symptoms (4 questions), quality of life (3 questions), and additional information (5 questions). In addition to the aforementioned items, there is a dynamic domain (one question) that is only asked on the second visit.

    Time frame: 14 days

  2. Clinical reliability

    The linguistically validated, translated Arabic version of the Acute Cystitis Symptom Score questionnaire should be able to recognize patients with acceptable specificity and sensitivity. The sum of the "typical symptoms," "deferential symptoms," and "quality of life" domain scores can range from 0 to 18, 0 to 12, and 0 to 9, respectively. The lower score signifies less severity; the top score is the most severe grade for each domain. The "additional" domain consists of five "yes" or "no" questions designed to discover if there are any criteria that may exclude the diagnosis of uncomplicated cystitis or produce similar symptoms. The sum of the "typical symptoms" domain alone will be tested for its diagnostic reliability. In addition, the sum of both "typical symptoms" and "quality of life" domains is also to be tested for its diagnostic reliability.

    Time frame: 7 months

07

Study locations

2 of 2 sites recruiting
  • Al-Elwiya Maternity Teaching Hospital
    Baghdad, 10064, Iraq
    Recruiting
    • Zahraa Muhmmed Jameel Al-Sattam, FICMS (Gyn.) · Principal investigator
    • Weqar Akram Hussein, FICMS (Gyn.) · Sub investigator
  • Alkindy Teaching Hospital
    Baghdad, 10064, Iraq
    Recruiting
    • Harth Mohamed Kamber, FICMS (Uro.) · Contactharthkamber@kmc.uobaghdad.edu.iq · +9647706029071
    • Harth Mohamed Kamber, FICMS (Uro.) · Principal investigator
    • Ahmed Abed Marzook, FICMS · Sub investigator
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06267040
Lead sponsor
Al-Kindy College of Medicine
Responsible party
Sponsor
First posted
Feb 20, 2024
Start date
Sep 1, 2023
Primary completion
Apr 15, 2024 (estimated)
Completion
Apr 30, 2024 (estimated)
Last update
Apr 16, 2024

Study contacts

Harth Mohamed Kamber, FICMS (Uro.)
Contact
harthkamber@kmc.uobaghdad.edu.iq
+9647706029071
Harth Mohamed Kamber, FICMS (Uro.)
study chair · University of Baghdad / Alkindy College of Medicine
Zahraa Muhmmed Jameel Al-Sattam, FICMS (Gyn.)
principal investigator · University of Baghdad / Alkindy College of Medicine
Weqar Akram Hussein, FICMS (Gyn.)
principal investigator · University of Baghdad / Alkindy College of Medicine
Ahmed Abed Marzook, FICMS
principal investigator · Dijlah University College

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion